No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses
- PMID: 26318165
- PMCID: PMC4577136
- DOI: 10.1073/pnas.1513441112
No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses
Conflict of interest statement
The authors declare no conflict of interest.
Comment in
-
Reply to Dimitrov et al.: VelociSuite technologies are a foundation for rapid therapeutic antibody development.Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):E5116. doi: 10.1073/pnas.1513935112. Epub 2015 Aug 28. Proc Natl Acad Sci U S A. 2015. PMID: 26318164 Free PMC article. No abstract available.
Comment on
-
Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43. doi: 10.1073/pnas.1510830112. Epub 2015 Jun 29. Proc Natl Acad Sci U S A. 2015. PMID: 26124093 Free PMC article.
References
-
- Jiang L, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med. 2014;6(234):234ra59. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
